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REVIEW
Abstract: Duloxetine is a balanced selective serotonin norepinephrine reuptake inhibitor 
(SNRI) which, in 2004, became the ﬁ  rst agent to receive regulatory approval for the treatment 
of painful diabetic neuropathy in the US. This compound has no other signiﬁ  cant receptor or 
channel activities other than the serotonin and norepinephrine reuptake inhibition mechanisms 
and works to diminish or control the symptoms of diabetic neuropathy. Duloxetine has no known 
neuroprotective or other effects which prevent the development of neuropathy in patients with 
diabetes. The purpose of this review article is to discuss the background of painful diabetic 
neuropathy, the pharmacology of duloxetine, and its safety and efﬁ  cacy in clinical trials and 
long-term observations. The authors will also comment on its use in clinical practice. Results 
from controlled clinical trials reveal that duloxetine administered at 60 mg qd or 60 mg bid is 
efﬁ  cacious in treating diabetic neuropathic pain relative to placebo. Positive treatment outcomes 
are also seen for other measures of pain and quality of life. A minor but statistically signiﬁ  cant 
increase in blood glucose compared with placebo treated patients has been observed in con-
trolled clinical trials. Otherwise, controlled and open-label clinical studies have demonstrated 
a high degree of safety and tolerability for the compound. These ﬁ  ndings provide support for 
the proposed role of serotonin and norepinephrine as key mediators of the descending pain 
inhibition pathways of the brain stem and spinal cord.
Keywords: duloxetine, diabetic neuropathy, selective serotonin norepinephrine reuptake inhibitor 
(SNRI), central sensitization
Introduction
Diabetes mellitus affects over 18 million people in the United States alone. Individuals 
with long-standing disease are at increased risk for numerous medical complications 
associated with signiﬁ  cant morbidity and mortality (eg, atherosclerotic disease, renal 
failure, retinopathy, neuropathy). One of the most troubling of these complications 
is painful diabetic neuropathy, due in large part to its prevalence among diabetics, 
its effect on the sufferer’s quality of life (QOL), and the limited number of effective, 
tolerated therapies.
Diabetic neuropathy is a symmetrical peripheral polyneuropathy that results from 
nerve damage after prolonged periods of suboptimal glycemic control and is classiﬁ  ed 
based on the location of the nerves affected. These include:
1.  Peripheral: toes, feet, legs, hands, arms
2.  Autonomic: heart and vasculature, digestive tract, urinary tract, sex organs, sweat 
glands, and the eyes
3.  Proximal: thighs, hips, buttocks
4.  Focal: eyes, facial muscles, ears, pelvis and lower back, thigh, abdomen.
Approximately 10%–20% develop the painful version of this disorder (Hoke and 
Feasby 2000).
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Painful diabetic neuropathy most likely occurs as a result 
of metabolic changes in the neurons as well as hyperglycemia-
associated microvascular damage that lead to abnormal 
signaling from the peripheral nociceptor that is perceived in 
the brain as pain (Hoke and Feasby 2000; Wada and Yagihashi 
2005). Over time “central sensitization” occurs, leading to 
further propagation and continuation of neuropathic pain. 
Central sensitization refers to neural plasticity and functional 
changes in the central nervous system (CNS) pain processing 
pathways that may result in a state of heightened sensitivity to 
painful stimuli, increased perception of non-painful stimuli as 
painful, and in some cases, the development of persistent pain 
in the absence of any stimulus (Woolf and Mannion 1999). 
In normal neural functioning, descending pain inhibition 
pathways in the brainstem dampen the strength of incoming 
nociceptive signaling from the periphery. In chronic diabetic 
neuropathic pain, the functionality of these descending 
pain inhibition pathways may be reduced, further amplify-
ing pain perception. Although the exact pathophysiologic 
mechanism of diabetic neuropathy is not clearly delineated, 
it is widely recognized that disinhibition and imbalance of 
5-hydroxytryptamine (5-HT) and norepinephrine (NE) in 
endogenous pain inhibitory pathways could contribute to 
persistent pain mechanisms.
Empirical evidence has suggested that tricyclic anti-
depressant (TCA) medications are useful as treatment for 
chronic pain syndromes, including diabetic neuropathy. 
Those that possess both 5-HT and NE reuptake blockade 
characteristics (eg, amitriptyline, desipramine) appear 
to have the best efﬁ  cacy but their use is limited by side 
effects (eg, sedation, hypotension, anticholinergic effects, 
cardiovascular abnormalities; Lynch 2001). These side 
effects are likely due to the afﬁ  nity of those compounds 
to cholinergic and adrenergic receptors and possibly due 
to sodium channel blocking capacities. Duloxetine is a 
selective inhibitor of reuptake of both 5-HT and NE that 
is relatively balanced in its activity without signiﬁ  cant 
effects at other sites. Due to its dual effects on 5-HT and NE 
reuptake, duloxetine has also been studied and approved 
for use in reducing diabetic neuropathic pain. Because of 
the prevalence and disabling nature of diabetic neuropa-
thy, this represents a signiﬁ  cant addition to the clinician’s 
armamentarium in providing care for diabetic patients. 
An understanding of the pharmacology and appropriate 
medical use of the compound for this painful condition 
will help ensure that patients receive optimal beneﬁ  t from 
its use. This review article pools the data from published 
RCTs and open-label studies evaluating the efﬁ  cacy of 
duloxetine for painful diabetic neuropathy.
Chemistry
Duloxetine hydrochloride, (+)-(S)-N-methyl-gamma-
(1-naphthyloxy)-2-thiophenepropylamine hydrochloride, is 
a selective serotonin and norepinephrine reuptake inhibitor, 
with molecular weight of 333.88. It is slightly soluble in 
water and exists as a white to slightly brownish-white solid 
(Cymbalta®; duloxetine HCl, Eli Lilly, Indianapolis, IN, 
USA, full prescribing information).
Pharmacodynamic proﬁ  le
Duloxetine is a selective inhibitor of both serotonin (5-HT) and 
norepinephrine (NE) reuptake, and is classiﬁ  ed as a selective 
serotonin norepinephrine reuptake inhibitor (SNRI). It pos-
sesses central pain inhibitory actions, probably related to its 
potentiation of serotonergic and noradrenergic activity in the 
CNS. Both 5-HT and NE have important neurotransmission 
activities in the descending pain inhibition pathways of the 
brainstem and spinal cord. Furthermore, these neurotransmitters 
are felt to act in a synergistic manner to reduce the transmis-
sion of pain signals from the periphery to the CNS (Yaksh 
1985; Zhou and Gebhart 1997). Duloxetine has been shown 
to be effective in animal models of persistent pain, including 
neuropathic pain. Presumably the analgesic effect of duloxetine 
is related to augmentation of 5-HT and NE mediated inhibitory 
pain pathways resulting in the decreased perception of pain.
Importantly, duloxetine has been demonstrated to have no 
signiﬁ  cant activity at muscarinic, histamine-1, α1-adrenergic, 
dopaminergic, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2C, 
and opioid receptors. Furthermore, duloxetine has been  Figure 1 Chemical structure of duloxetine.
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demonstrated to have no activity on ion channels including 
Na+ channels (Bymaster et al 2001). It has, however, been 
shown to have balanced activity as an inhibitor of 5-HT and 
NE reuptake with very low activity on dopamine reuptake 
(Wong et al 1993; Wong and Bymaster 2002). Based on 
what is known about the activity of endogenous inhibitory 
pathways, a compound with these actions could possibly have 
good efﬁ  cacy in treatment of neuropathic pain processes and 
possess an acceptable side-effect proﬁ  le.
Duloxetine has been studied extensively in pre-clinical 
animal models of both persistent neuropathic pain and acute 
nociceptive pain. Its activity was compared in these experi-
ments to that of a selective serotonin reuptake inhibitor 
(paroxetine); norepinephrine reuptake inhibitors (thion-
isoxetine and desipramine), and other SNRIs (venlafaxine, 
milnacipran, amitriptyline). In the neuropathic pain study 
paradigms (the formalin model and the L5/L6 nerve liga-
tion model, both in rats), the performance of duloxetine 
was numerically greater (although not statistically supe-
rior) to the comparator drugs at doses which did not lead 
to neurologic side effects. However, duloxetine did not 
demonstrate efﬁ  cacy in the tail-ﬂ  ick model of nociceptive 
pain, indicating a lack of a primary analgesic or anesthetic 
effect of the drug. These data demonstrate that duloxetine 
has potential for the treatment of persistent neuropathic pain 
owing to its ability to inhibit both 5-HT and NE reuptake 
(Iyengar et al 2004).
Duloxetine has several putative phase I metabolites, 
including 4-hydroxy-, 5-hydroxy-, 6-hydroxy-, 5-hydroxy-
6-methoxy-, 6-methoxy-5-hydroxy-, 5,6-dihydroxy-, and 4,6-
dihydroxyduloxetine, as well as phase II glucuronide and sulfate 
conjugates. In vitro binding studies have shown that none of 
these circulating metabolites contributes signiﬁ  cantly to the 
pharmacologic activity of duloxetine (Kuo et al 2004).
Pharmaceutics
Duloxetine is available in capsules which contain enteric-coated 
pellets of duloxetine hydrochloride. The drug is degradable in 
the acidic milieu of the stomach, which necessitates the enteric 
coated pellets to allow the compound to be principally absorbed 
in the small intestine. It is extremely important that capsules of 
duloxetine not be chewed or crushed thereby compromising 
the integrity of the enteric coating. The capsules are marketed 
containing 22.4, 33.7, and 67.3 mg of duloxetine hydrochloride 
to provide equivalent doses of 20, 30, and 60 mg of duloxetine 
respectively. There are a few inactive ingredients in the cap-
sules, including: FD&C Blue No. 2, gelatin, hypromellose, 
hydroxypropyl methylcellulose acetate succinate, sodium 
lauryl sulfate, sucrose, sugar spheres, talc, titanium dioxide, 
and triethyl citrate. The 20 and 60 mg capsules contain iron 
oxide yellow as well (Anderson et al 1996).
Pharmacokinetics
Absorption
Following administration of duloxetine hydrochloride there 
is a 2 hour delay in absorption, owing to the enteric coated 
pellets previously discussed. It is then well-absorbed, achiev-
ing maximal plasma concentrations (Cmax) about 6 hours 
post dosing (time to maximal concentration, or Tmax). Steady 
state plasma concentrations are usually accomplished about 
3 days after initiation of therapy. The Cmax for duloxetine is 
not affected by food, but the Tmax is prolonged from 6 hours 
to 10 hours when given with the food present in the gastro-
intestinal tract. Furthermore, the overall extent of absorption 
(area under the curve, or AUC) is reduced by about 10% 
when administered with food. Studies demonstrate a 3 hour 
delay in absorption of drug in the evening dose as compared 
to that of the morning dose.
Distribution
The apparent volume of distribution (VD) of duloxetine is 
known to be 1640 L. It is highly bound to plasma proteins 
(>90%), but the interactions between this drug and other 
highly plasma protein-bound compounds have not been 
adequately studied. The principal proteins involved in the 
binding of duloxetine include albumin and α1-acid gly-
coprotein. The plasma protein binding of duloxetine is not 
signiﬁ  cantly affected by hepatic or renal insufﬁ  ciency.
Metabolism
The elimination half-life (t1/2) of duloxetine is about 12 
hours (range: 8–17 hours). It undergoes extensive hepatic 
metabolism to inactive compounds. This is mostly carried 
out by the cytochrome P-450 isoenzymes, 2D6 and 1A2, 
which catalyze the oxidation of the naphthyl ring. These 
metabolites are subsequently conjugated and then either 
eliminated or oxidized further prior to elimination. There 
are many apparent metabolites as previously discussed, 
but the two major ones are 4-hydroxy-duloxetine gluc-
uronide and 5-hydroxy-6-methoxy-duloxetine sulfate. 
All others represent only minor routes of transformation 
(Kuo et al 2004).
Elimination
Less than 1% of the given dose of duloxetine appears in 
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Smith and Nicholson
appears in the urine as inactive metabolites. Only about 20% 
is eliminated in the feces (Lantz et al 2003).
Interactions with other drugs
Since the principal metabolism pathways of duloxetine are 
through the cytochrome P450 isoenzymes 1A2 and 2D6 
(CYP1A2 and CYP2D6), it would be anticipated that drugs 
that interfere with or alter the activity of these hepatic enzymes 
would potentially alter the blood levels of duloxetine in the 
patient to which the drugs were co-administered. Since dulox-
etine is not a substrate, inhibitor, or inducer of the important 
CYP3A4, there are no concerns regarding co-administration 
with drugs known to affect that metabolic enzyme, such as 
macrolide antibiotics or antifungal agents. Duloxetine has 
no important or measurable effects on and is not a substrate 
for monoamine oxidase. However, because serious problems 
have resulted from the co-administration of SSRI with a 
monoamine oxidase inhibitor (MAOI), duloxetine should not 
be given in combination with any MAOI or within 2 weeks 
of discontinuing an MAOI. Further, an MAOI should not be 
started within 5 days of discontinuing duloxetine. Clinically 
speaking, there are only a few other concerns of note that 
involve drugs handled by the CYP1A2 and CYP2D6 systems 
that require attention by the prescriber.
Inhibitors of CYP1A2
Pharmacokinetic studies looked at the interaction between 
duloxetine and ﬂ  uvoxamine, a known potent inhibitor of 
CYP1A2. The results demonstrated a 5-fold increase in the 
AUC for duloxetine and a 2.5-fold in the Cmax. The t1/2 of 
duloxetine was increased approximately 3-fold. Other drugs 
known to inhibit CYP1A2 include cimetidine and quinolone 
antibiotics such as ciproﬂ  oxacin.
Inhibitors of CYP2D6
Paroxetine is a moderate inhibitor of CYP2D6. A pharma-
cokinetic study was done looking at the serum concentra-
tion curves of duloxetine when concomitantly administered 
with low to moderate doses of paroxetine (20 mg), showing 
increases in both the AUC and Cmax of 60% for duloxetine. 
Other medications with similar actions on CYP2D6, such as 
ﬂ  uoxetine and quinidine, would be expected to have similar 
effects on the concentration of duloxetine and should be used 
with caution together with this drug (Skinner et al 2003).
Drugs metabolized by CYP1A2
Duloxetine has no ability to induce CYP1A2, but is known to 
have mild inhibitory effects on the enzyme in vitro. In clinical 
pharmacokinetic studies, there were no signiﬁ  cant effects 
seen in the concentration of CYP1A2 substrates such as 
theophylline when co administered with duloxetine given 
60 mg bid. Therefore, duloxetine is not felt to have signiﬁ  -
cant effects on drugs metabolized by the CYP1A2 system 
(DiVirgilio 2002).
Drugs metabolized by CYP2D6
Duloxetine is a moderate inhibitor of the actions of CYP2D6 
and requires caution when co-administering agents metabo-
lized by that system. Duloxetine has been shown to increase 
the AUC of desipramine 2.9-fold and its Cmax by 70% when 
coadministered (Skinner et al 2003). Because of this effect, 
certain other drugs including other TCAs (nortriptyline, 
amitriptyline, and imipramine), phenothiazines, and type 
1C anti-arrhythmics (ﬂ  ecainide, propafenone) should be 
administered at a lower dose than usual and monitored care-
fully. Because of the risk of fatal arrhythmia, duloxetine 
should not be co-administered with thioridazine under any 
circumstance.
Other drug–drug interaction concerns
There are theoretical concerns that the co-administration of 
duloxetine with medications that raise the gastrointestinal pH 
could result in a hastened dissolution of the enteric coating 
of the pellets of duloxetine. The concern would be that the 
drug might be more readily and rapidly absorbed under these 
conditions. However, co-administration studies done with 
aluminum and magnesium hydroxide suspension and with 
famotidine showed no change in the pharmacokinetics of a 
40 mg dose of duloxetine. Studies have not been conducted 
with proton pump inhibitors (Sathirakul 2002).
Any CNS-acting medication should be used with cau-
tion when administered to patients already on other CNS-
acting medications. Sedation or other impairment of CNS 
functioning could occur sporadically and without warning 
in individual patients. Therefore cautious use is warranted. 
Speciﬁ  c pharmacokinetic interactions with benzodiazepines 
have not been demonstrated in studies. There appears to be 
no signiﬁ  cant interaction with alcohol on initial evaluation 
(Skinner and Weerakkody 2002).
Clinical efﬁ  cacy
The clinical efﬁ  cacy of duloxetine for pain associated with 
diabetic peripheral neuropathy has been demonstrated in 
three double-blind, placebo-controlled, randomized studies. 
These studies (n = 1139) were 12-week ﬁ  xed-dose trials 
(Goldstein et al 2005; Raskin et al 2005; Wernicke et al Vascular Health and Risk Management 2007:3(6) 837
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2006a) that enrolled Type I or Type II diabetics with pain-
ful diabetic neuropathy for greater than 6 months duration 
with at least moderate 24-hour pain severity. All three trials 
randomized participants to a duloxetine 60 mg qd, dulox-
etine 60 mg bid, or placebo treatment arm. Goldstein et al 
(2005) also included a 20 mg qd treatment arm. In all three 
trials, investigators excluded patients with major depres-
sive disorder (MDD). The primary efﬁ  cacy end point for 
all studies was mean change on average daily pain severity 
(measured using an 11-point Likert-type pain scale from 
baseline to the end of the 12-week dosing period. Secondary 
endpoints included other pain diary outcomes (24-hour worst 
pain, night pain), clinician/patient global impressions (CGI, 
PGI), scales from the Brief Pain Inventory (BPI), a QOL 
measure (Short Form-McGill Pain Questionniare; SF-MPQ), 
dynamic allodynia, and the Hamilton Depression Rating 
Scale (HAM-D17).
Participant proﬁ  le and weekly outcomes
Table 1 shows the baseline characteristics of patients for 
all studies. A total of 77.8% of subjects completed the 
trials. Figure 2 shows that in all 3 trials, subjects in the 
duloxetine 60 mg qd or 60 mg bid treatment arm reported 
a greater decrease in 24-hour average pain severity 
relative to placebo after the ﬁ  rst week and this effect was 
maintained throughout the 12-week dosing period. In the 
Goldstein et al (2005) trial, subjects in the 20 mg arm did 
not show signiﬁ  cant pain reduction relative to placebo. 
Figure 2 also shows that in all 3 studies, the reduction in 
24-hour average pain severity was consistent with a dose 
dependent response.
Pooled outcomes and analysis
of effect sizes
In order to gain a better sense of treatment effects across all 
studies and to assess more accurately the magnitude of dif-
ferences among treatment arms and placebo (termed “effect 
size”), outcome data were combined across studies. Figure 3 
shows the change in the primary outcome; the 24-hour pain 
diary score from baseline to week 12 and change in two other 
pain diary measures (24-hour worst pain and night pain). 
Figure 4 shows the change in the BPI scales (severity, interfer-
ence, general activity) from baseline to week 12. Both the 60 
mg qd and the 60 mg bid arms showed signiﬁ  cant reductions 
(all p < 0.001) across all pain diary measures and BPI scales 
relative to changes seen in the placebo arm. Table 2 shows 
the mean change from baseline to week 12 on the CGI, PGI, 
SF-MPQ, dynamic allodynia, and HAM-D17 for each treatment 
arm. Duloxetine 60 mg qd showed signiﬁ  cant improvement 
on CGI, SF-MPQ and decreased dynamic allodynia relative to 
placebo. Duloxetine 60 mg bid showed signiﬁ  cant improve-
ment on CGI and SF-MPQ relative to placebo.
Table 3 shows the mean difference in effect size (ES; 
with 95% CI for the effect) for each outcome. ES was cal-
culated using Cohen’s d. Looking at ES allows the reader to 
better ascertain the magnitude of group differences as well 
as provide a hint of whether this difference is considered 
“clinically relevant” (where higher ES is reﬂ  ective of a 
greater clinical relevance). By convention, Cohen’s d <0.2 = 
negligible difference; 0.2–0.49 = small; 0.5–0.79 = medium; 
0.8 = large. The table shows that there was a medium 
effect for improvement in average 24-hour pain for both 
treatment arms relative to placebo. There also was a medium 
ES seen when comparing change in the duloxetine 60 mg 
bid and placebo arms for the following: 24-hour worst pain, 
BPI severity, CGI, and SF-MPQ. There was a small ES 
seen when comparing change in the duloxetine 60 mg bid 
and placebo arms for the following: night pain, BPI general 
activity and BPI interference. There was a small ES seen 
when comparing change in the duloxetine 60 mg qd arms 
and placebo for the following: 24-hour worst pain, night 
pain, BPI severity, BPI general activity, BPI interference, 
CGI, and SF-MPQ. There was also a statistically signiﬁ  cant 
difference between change in dynamic allodynia between 
the duloxetine 60 mg qd and placebo arms; however, the 
Table 1 Baseline characteristics of patients
    Mean or   SD
   Percentage 
Age   59.88  10.57
Female   43% 
Race    
 Caucasian  84% 
 African-American  4%
 Hispanic  9% 
 Other  3% 
Weight (kg)    94.38  21.12
Diabetes Type     
 Type  I  12% 
 Type  II  88% 
Years with diabetes     11.74  9.45
Years with diabetic neuropathy    3.91  4.10
Michigan Neuropathy    5.26  1.54
Screening Instrument     
Average 24 hour Pain Severity    5.87  1.45
CGI- Severity    4.49  0.87
HAM-D17 Total Score    3.66  3.20
Abbreviations: CGI, Clinical Global Impression; SD, standard deviation; HAM-D17, 
17-item Hamilton Depression Rating Scale.Vascular Health and Risk Management 2007:3(6) 838
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Figure 3 Pooled mean change (baseline-week 12) for pain diary scores in duloxetine-treated patients. *Both treatment arms showed signiﬁ  cant improvement (p < 0.001) 
from baseline to end of treatment period on all measures relative to change seen in placebo.
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Figure 2 Primary efﬁ  cacy measure (24 hour average pain severity score) in duloxetine-treated patients with pain associated with diabetic neuropathy. Reproduced with 
permission from Goldstein D, Lu Y, Detke MJ et al 2005. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain, 116:109–18. Copyright © IASP®.
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ES was considered negligible and is thus of little or no 
clinical relevance.
The investigators in all three studies concluded that 
duloxetine 60 mg qd and 60 mg bid were effective for 
treating pain associated with diabetic neuropathy. All three 
studies argued that the data conﬁ  rmed the proposed role of 
5-HT and NE as key mediators of descending pain pathways. 
They also suggested that 5-HT and NE reuptake inhibition 
by duloxetine may offer an effective and safe alternative 
for the treatment of persistent pain states. Moreover, since 
differences in pain did not correlate with changes in mood 
(as measured by change in the HAM-D17) and patients with 
MDD were excluded, it was apparent that the pain relief was 
not due to improvement in depression.
Safety and tolerability
Safety and tolerability of controlled trials
Safety and tolerability was evaluated for all three con-
trolled trials as well as three long term (52 week) open 
label studies (Raskin et al 2006; Wernicke et al 2006a, b, 
2007). We will ﬁ  rst report the safety and tolerability 
ﬁ  ndings of the blinded trials. Overall, 67/339 (19.7%) 
discontinued during the study period. Figure 5 shows 
the pooled percentage that discontinued from each arm 
among the controlled trials (Goldstein et al 2005; Raskin 
et al 2005; Wernicke et al 2006a, b). In regards to serious 
adverse events (SAEs), a total of 41/1139 (3.6%) patients 
reported at least one SAE; however, SAEs did not differ 
among groups. Goldstein et al (2005) and Wernicke et al 
(2006a, b) included the treatment emergent adverse events 
(TEAEs) for each group as well as lipid proﬁ  les. Figure 6 
shows the percentages of individuals who experienced 
the most common TEAEs. Table 4 shows the pooled 
changes in lipid proﬁ  les and glycosylated hemoglobin 
(HbA1c). The only group difference was for high density 
lipoprotein (HDL) between the duloxetine 60 mg bid and 
placebo treatment arms; however, the difference (0.027) 
is not clinically signiﬁ  cant.
Figure 4 Pooled mean change (baseline-week 12) for Brief Pain Inventory (BPI) subscales. *Both treatment arms showed signiﬁ  cant improvement (p < 0.001) from baseline 
to end of treatment period on all measures relative to change seen in placebo.
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Safety and tolerability of long-term open 
label trials
Discontinuation and adverse events
Within the long-term open label trials (Raskin et al 2006; 
Wernicke et al 2006a, b, 2007) participants were assigned 
to either a duloxetine 60 mg bid or routine care arm (at a 
2:1 ratio, respectively). The completion rate was 77.6% 
(450/580) for the duloxetine 60 mg bid arm and 83.6% 
(240/287) for the routine care arm. A total of 150/867 (17.3%) 
patients reported at least one SAE; however, SAEs did not 
differ between arms. A total of 6.3% (18/287) in the routine 
care arm discontinued due to a SAE compared with 10.2% 
(77/689) in the duloxetine 60 mg bid arm (this difference 
was not signiﬁ  cant). Raskin et al (2006) and Wernicke et al 
(2007) reported no signiﬁ  cant group differences for TEAEs. 
Wernicke et al (2006) reported 8 TEAEs that occurred more 
frequently in the routine care group. The only TEAE that was 
reported by >5% in the duloxetine 60 mg BID arm for all 
three studies was nausea. No TEAE was reported by >5% 
in the routine care arm for all three studies.
Lipid proﬁ  les and HbA1c
Within the open label trials, 52-week lipid proﬁ  le change 
analysis showed no consistent pattern of group differences. 
Raskin et al (2006) reported a greater decrease in HDL in 
the routine care group (p < 0.001), Wernicke et al (2006a, b) 
reported a grater decrease in low density lipoprotein (LDL) 
in the routine care group (p < 0.001), and Wernicke et al 
(2007) reported a greater increase in HbA1c in the duloxetine 
group.
Analysis of chemistry/urinalysis
Table 5 summarizes the changes in chemistry analytes and 
urinalysis from baseline to endpoint. Signiﬁ  cant differ-
ences were seen between groups on six laboratory values. 
Table 3 Effect sizes for mean differences comparing duloxetine 
60 mg qd and 60 mg bid with placebo
  60 mg qd vs   60 mg bid vs Placebo
  placebo(99% CI)  (99% CI)
24-hour average pain   0.51**  0.56**
score  (0.28, 0.75)  (0.32, 0.80)
24-hour worst pain score  0.47*  0.53**
  (0.21, 0.73)  (0.27, 0.79)
Night pain score  0.40*  0.48*
  (0.15, 0.65)  (0.22, 0.73)
BPI severity  0.42*  0.51**
  (0.18, 0.66)  (0.26, 0.75)
BPI general activity  0.32*  0.39*
  (0.07, 0.57)  (0.14, 0.64)
BPI interference  0.37*  0.46*
  (0.17, 0.57)  (0.25, 0.66)
CGI severity  0.44*  0.53**
  (0.32, 0.56)  (0.40, 0.65)
PGI improvement  N/A  N/A
SF-MPQ total  0.43*  0.53**
  (0.03, 1.18)  (0.05, 1.28)
Dynamic Allodynia  0.17  NA
HAM-D17 Total Score  (0.13, 0.21)  N/A
 N/A
*small effect, ** medium effect, *** large effect; N/A = no signiﬁ  cant difference on 
that measure between that treatment arm and placebo. 
Effect sizes were calculated using Cohen’s d. By convention, Cohen’s d < 0.2 = 
negligible difference; 0.2–0.49 = small; 0.5–0.79 = medium; ≥0.8 = large. 
Abbreviations: BPI, Brief Pain Inventory; CGI, Clinical Global Impression; PGI, 
Patient’s Global Impression; SF-MPQ, Short Form McGill Pain Questionnaire; 
HAM-D17, 17-item Hamilton Depression Rating Scale.
Table 2 Mean change and 95% CI for mean difference between treatment arm and placebo from baseline on secondary
outcome measures 
  Placebo  Duloxetine 60 mg qd  Duloxetine 60 mg bid
  mean  Mean change   Mean change 
  change   (95% CI of difference   (95% CI of difference 
    from placebo)  from placebo)
CGI severity  –0.91  –1.40*   –1.52*
Diff. from placebo (95% CI)    –0.49 (–0.66, –0.32)  –0.61 (–0.79, –0.43)
PGI improvement  3.04  2.44  2.39 
Diff. from placebo (95% CI)    –0.60 (–1.46, 0.27)   –0.65 (–1.45, 0.17)
SF-MPQ total  –4.86  –7.64*   –8.32*
Diff. from placebo (95% CI)    –2.79 (–3.83, –1.74)  –3.46 (–4.51, –2.41)
Dynamic allodynia  –0.10  –0.16*  –0.14 
Diff. from placebo (95% CI)    –0.06 (–0.12, –0.03)   –0.04 (–0.09, 0.02)
HAM-D17 Total Score  –0.59  –0.92   –0.23 
Diff. from placebo (95% CI)    –0.33 (–0.71, 0.06)  0.36 (–0.03, 0.76)
*p < 0.05. 
Abbreviations: BPI, Brief Pain Inventory; CGI, Clinical Global Impression; PGI, Patient’s Global Impression; SF-MPQ, Short Form McGill Pain Questionnaire; HAM-D17,
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Albumin g/L, alanine transaminase/serum glutamate pyru-
vate transaminase (ALT/SGPT) U/L, aspartate transaminase/
serum glutamate oxaloacetic transaminase (AST/SGOT) 
U/L, total cholesterol mmol/L, gamma-glutamyl transferase 
(GGT) U/L, and fasting glucose all showed a greater increase 
among those in the duloxetine 60 mg bid arm relative to 
the increase among those in the routine care arm. Further 
examination of the ES indicated that all of the differences 
were negligible except for glucose and cholesterol (where 
the ES was small).
QOL measures
Figure 7 shows the changes in SF-36 measures from baseline 
to endpoint. A decrease on the SF-36 indicates a poorer QOL. 
Those in the routine care group showed greater decreases on 
all SF-36 subscales relative to change in the duloxetine 60 
mg bid arm. These differences were signiﬁ  cant for the bodily 
pain, physical component, and physical role subscales. In 
addition, those in the routine care arm had a signiﬁ  cantly 
greater decrease from baseline to endpoint as measured by 
the European QOL (indicating a poorer QOL) scale relative 
to change among those in the duloxetine 60 mg bid arm. 
A decrease on the SF-36 scales and European QOL indicate 
a poorer QOL.
Conclusions and expert opinion
Research and clinical experience in the last decade has con-
tributed to new and clearer understanding of the physiology 
surrounding descending pain inhibition pathways of the 
brainstem and spinal cord. The advantages of balanced 
5-HT and NE reuptake inhibition as a pharmacotherapeutic 
modality are essentially without challenge. Duloxetine has the 
unique proﬁ  le of dual 5-HT and NE reuptake inhibition in a 
Table 4 Mean change in HbA1c and lipid proﬁ  le from baseline to 
end point for controlled trials 
 Placebo  Duloxetine    Duloxetine 
    60 mg qd  60 mg bid
HbA1c (%) –0.001  –0.001  <0.0004
HDL cholesterol (mmol/L)  0.012  0.014  0.039*
LDL cholesterol (mmol/L)  0.012  0.007  0.052
Triglycerides (mmol/L)  0.12  0.24  −0.25
*p < 0.05 indicating difference between 60 mg bid and placebo. 
Abbreviations: HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; 
LDL, low-density lypoprotein.
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balanced fashion with little or no other receptor or channel 
effects. This relatively “clean” mechanism of action places 
this compound in position to provide relief of chronic pain 
syndromes, such as painful diabetic neuropathy, without the 
signiﬁ  cant side effect issues associated with routine current 
and past therapies.
Data from both short and long term trials shows that 
duloxetine consistently provides signiﬁ  cantly more diabetic 
neuropathic pain relief than either placebo or routine care. 
This is seen in both pain measures and QOL measures 
assessing the impact pain has on functioning. In long-term 
trials, there are few side effects from using duloxetine that 
would decrease patient adherence. There is a small (but 
clinically insigniﬁ  cant) increase in HDL among those tak-
ing duloxetine relative to placebo in short-term controlled 
trials. In the long-term open label studies, small differences 
are seen in fasting glucose, albumin, GGT, AST/SGOT, 
ALT/SGPT, and total cholesterol among those taking 
duloxetine relative to routine care. When considering 
the current ﬁ  ndings, it is important to note that the USPI 
for duloxetine notes small increases in fasting glucose in 
short-term controlled trials and small increases in HbA1c 
Table 5 Mean change in chemistry/urinalysis proﬁ  les from baseline to end point for long-term open-label studies 
  Routine   Duloxetine 60 mg  Difference (95% 
  care change  bid mean change  CI of difference)
Albumin, g/L  –0.13  43.61  43.74*
     (12.31,  75.20)
Alkaline phosphate, U/L  2.32  4.78  2.46
     (–0.09,  5.02)
ALT/SGPT, U/L  –1.85  0.47  2.32*
     (0.58,  4.06)
AST/SOGT, U/L  –1.70  0.23  1.93*
     (0.49,  3.37)
Bicarbonate, HCO3, mmol/L  0.45  0.50  0.05
     (–0.34,  0.44)
Bilirubin, total, μmol/L –0.74  –0.80  –0.06
     (–0.53,  0.40)
Calcium, mmol/L  0.01  0.01  <0.01
     (–0.01,  0.02)
Chloride, mmol/L  0.60  –0.69  –1.29
     (–1.85,  0.73)
Cholesterol, total, mmol/L  –0.18  0.07  0.25*
     (0.09,  0.40)
Creatine phosphokinase, U/L  –2.87  –4.28  –1.41
     (–21.45,  18.62)
Creatinine, μmol/L 3.55  1.10  –2.45
     (–4.78  0.11)
GGT, U/L  –3.69  0.56  4.27*
     (0.15,  8.37)
Glucose, fasting, mmol/L  –0.65  0.66  1.31*
     (0.63,  1.99)
Inorganic phosphorus, mmol/L  0.01  0.02  0.01
     (–0.02,  0.04)
Potassium, mmol/L  0.02  0.02  <0.01
     (–0.06,  0.07)
Protein, total, g/L  0.o57  0.49  –0.08
     (–0.67,  0.50)
Sodium, mmol/L  0.16  –0.60  –0.76
     (–1.27,  0.25)
Urea nitrogen, mmol/L  0.42  0.22  –0.20
     (–0.50,  0.10)
Uric acid, μmol/L 17.53  –3.23  –20.30
     (–30.22,  11.31)
*p < 0.05 
Abbreviations: ALT/SPGT, alanine transaminase/serum glutamate pyruvate transaminase; AST/SOGT, aspartate transaminase/serum glutamate oxaloacetic transaminase; 
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in long-term trials relative to placebo or routine care (Eli 
Lilly and Company 2007). However, the magnitude of these 
differences is not clinically signiﬁ  cant and thus should not 
be a major concern for most patients.
The pain of diabetic peripheral neuropathy is one of 
the more severe and debilitating complications of diabetes 
mellitus. Diminished physical functioning, poor sleep, and 
psychologic comorbidities contribute to poorer QOL among 
those with this condition. Accordingly, one can easily under-
stand how patients with painful diabetic neuropathy begin to 
slip into a downward spiral of decreasing physical activity, 
depression, poor self-care, worsening hyperglycemia, and 
progressive neuropathic pain. The regulatory approval of 
duloxetine for use in diabetic neuropathy is a milestone in 
pain management as it represents the ﬁ  rst approved agent 
for this condition. Other agents have since followed, further 
contributing to a better understanding of the mechanisms of 
central sensitization and the neuroplastic changes associated 
with chronic and neuropathic pain.
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